A combination of KN026, a novel bispecific antibody, and docetaxel elicited responses with an acceptable toxicity profile when administered as neoadjuvant treatment in patients with HER2-positive (HER2+) early or locally advanced breast cancer.
Ryan Scott
Advertisement
Articles by Ryan Scott
Adding pembrolizumab to combination of trastuzumab and chemotherapy improved progression-free survival vs placebo plus trastuzumab and chemotherapy in the first-line treatment of patients with metastatic HER2-positive gastric or gastroesophageal junction (GEJ) cancer.
Thanos Zomas, MD, global medical lead for lymphoma and leukemia and for the Adcetris Program, Takeda Oncology, discussed results of the ECHELON-1 trial.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Ongoing COVID-19 Circulation Linked to Increases in Health-Related Work Absences, Workforce Exits
2
After Narrow Miss in Phase 3 Study, IO Biotech Ponders Next Steps for Immune-Modulatory, Off-the-Shelf Cancer Vaccine
3
Guidelines for Bronchiectasis Highlight Multiple Treatment Methods
4
3 New Study Findings to Look Out for at Menopause Society 2025
5
